Guidance to Sponsors on How to Manage Clinical Trials during the COVID-19 Pandemic by European Union

Coronavirus management

The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic. The impact of the pandemic on European health systems and more broadly on society, will make it necessary for sponsors to adjust how they manage clinical trials and the people who participate in these trials. It is an extensive guidance to sponsors in response to coronavirus pandemic.

Please read full article here

Download Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic (PDF)

Latest Developments in Cancer

Leave a Comment

Your email address will not be published.

Previous reading
Guidance by NIH, CDC and FDA to Coronavirus Pandemic in the United States of America
Next reading
Our Response to Coronavirus Pandemic and Guidance to Cancer Patients